Seladelpar

ATC Code A05AX07

Seladelpar

Definition

An orally bioavailable agonist of peroxisome proliferator-activated receptor (PPAR)-delta (PPARd), with bile acids reducing activity. Upon oral administration, seladelpar targets, binds to and activates PPARd in the liver. This induces the expression of fibroblast growth factor 21 (FGF21), which downregulates CYP7A1, the key enzyme for the synthesis of bile acids from cholesterol. By reducing CYP7A1 expression, bile acid synthesis is reduced. This leads to reduced inflammation and scarring associated with primary biliary cholangitis (PBC).

Also known as SELADELPAR — per NCIT

Also identified as

Indications

Disease Relation Source
Primary biliary cholangitis may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Alimentary part of gastrointestinal system may treat a disease of this organ DERIVED · CC BY 4.0
Bile ducts may treat a disease of this organ DERIVED · CC BY 4.0
Liver may treat a disease of this organ DERIVED · CC BY 4.0

3 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.